Uncategorized

Merck posts ‘encouraging’ Phase 3 ulcerative colitis data but Roche challenge looms

Given its intravenous route of administration, Merck’s tulisokibart will likely “need to be meaningfully improved” over Roche’s afimkibart, which can be given subcutaneously, BMO Capital Markets analysts said. Both assets are being tested for ulcerative colitis.

Merck posts ‘encouraging’ Phase 3 ulcerative colitis data but Roche challenge looms Read More »

Scroll to Top